Updated global adult sepsis guidelines, released in October 2021 by the Surviving Sepsis Campaign (SSC), place an increased emphasis on improving the care of sepsis patients after they are discharged from the intensive care unit (ICU) and represent greater geographic and gender diversity than previous versions.
The new guidelines specifically address the challenges of treating patients experiencing the long-term effects of sepsis. Patients often experience lengthy ICU stays and then face a long, complicated road to recovery. In addition to physical rehabilitation challenges, patients and their families are often uncertain how to coordinate care that promotes recovery and matches their goals of care.
Updated global adult sepsis guidelines, released in October 2021 by the Surviving Sepsis Campaign (SSC), place an increased emphasis on improving the care of sepsis patients after they are discharged from the intensive care unit (ICU) and represent greater geographic and gender diversity than previous versions.
The new guidelines specifically address the challenges of treating patients experiencing the long-term effects of sepsis. Patients often experience lengthy ICU stays and then face a long, complicated road to recovery. In addition to physical rehabilitation challenges, patients and their families are often uncertain how to coordinate care that promotes recovery and matches their goals of care.
It includes new definition, pathophysiology, management of sepsis, septic shock and neutropenic sepsis and even newer evolving concepts or types of sepsis.
A simple presentation on hypokalemia. The most common electrolyte disorder in the Critical Care practice.The presentation is based on a mortality and morbidity case report and discussion. It covers all the basic aspects of understanding the causes of hypokalemia in ICU and its management. Target audience are residents ICU and ER but all health care workers can benefit.
Septic shock, updated presentation, including latest guidelines from Intensive care societies and how to approach to the diagnosis with few notes about Early Goal Directed Therapy and role of steroids
It includes new definition, pathophysiology, management of sepsis, septic shock and neutropenic sepsis and even newer evolving concepts or types of sepsis.
A simple presentation on hypokalemia. The most common electrolyte disorder in the Critical Care practice.The presentation is based on a mortality and morbidity case report and discussion. It covers all the basic aspects of understanding the causes of hypokalemia in ICU and its management. Target audience are residents ICU and ER but all health care workers can benefit.
Septic shock, updated presentation, including latest guidelines from Intensive care societies and how to approach to the diagnosis with few notes about Early Goal Directed Therapy and role of steroids
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to an infection.The definition of sepsis was updated in 2016 following publication of the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). This recommended that organ dysfunction should be defined using the Sequential (or Sepsis-related) Organ Failure Assessment (SOFA) criteria or the "quick" (q)SOFA criteria.
Ventilatory management of Acute Hypercapnic Respiratory FailureVitrag Shah
Presentation on ventilatory management in Acute Hypercapnic Respiratory Failure
Updated information till 17/8/16
For powerpoint format, contact dr.vitrag@gmail.com
http://www.medicalgeek.com/presentation/36513-ventilatory-management-acute-hypercapnic-respiratory-failure-presentation.html
Download review articles and guidelines for ventilatory management in COPD & Asthma
http://www.medicalgeek.com/articles-and-news/36514-articles-ventilatory-management-copd-asthma.html
Ventilatory management in obstructive airway diseasesVitrag Shah
Presentation on ventilatory management in COPD & Asthma
Updated information till 26/5/16
For powerpoint format, contact dr.vitrag@gmail.com
http://www.medicalgeek.com/presentation/36441-ventilatory-management-obstructive-airway-diseases-presentation.html
"Best Paper Presentation Award"
Presented at 3rd Annual Critical Care Medicine Conference , Sir Gangaram Hospital, New Delhi
"A Case of H1N1 ARDS - Journey from NIV to Invasive Ventilation to recruitment to proning to ECMO & Nitric Oxide"
For PPT, Check following link
http://www.medicalgeek.com/clinical-cases/36303-h1n1-ards-case-presentation.html
ARDS - Diagnosis and Management
Visit www.medicalgeek.com for more
http://www.medicalgeek.com/lecture-notes/36156-ards-diagnosis-management-presentation-ppt-pdf.html#post89045
https://www.facebook.com/MedicalGeek
https://only4medical.wordpress.com/
http://www.facebook.com/group.php?gid=129413628862&ref=nf
http://groups.yahoo.com/group/only4medical/
Tetanus Presentation
77 slides
Including drip rates of muscle relaxants
PDF : http://www.mediafire.com/download/k00ciibf73d7y6p/
For more, visit www.medicalgeek.com
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. Septic shock – Interactive Case
with recommendations
Dr.Vitrag Shah
MD Medicine, FNB Critical Care Medicine, EDIC
Consultant Physician and Chief Intensivist
Kiran Hospital, Surat
2. Clinical Decision Making
In rapidly developing clinical sciences
Concepts change
Procedures change
Technological evolution occurs
Up-to-date knowledge will benefit patients
3. Point to be discussed
1. Sepsis 1 to Sepsis 3 – Definition
2. Sepsis bundles
3. Interactive case
4. SSC 2016 recommendations on
Antibiotic, PCT
Fluid
Vasopressor
Nutrition
Others
5. Marik Protocol
4.
5. SEPSIS - 1
1.Temperature >38°C or <36°C;
2.Heart rate >90 beats per minute;
3.Respiratory rate >20 breaths per minute or PaCO2 <32 mmHg;
and
4.White blood cell count >12,000/cu mm, <4,000/cu mm, or >10%
immature (band) forms.
SIRS
Sepsis
Severe sepsis
Septic shock
Two or more of the SIRS criteria plus infection
sepsis associated with organ dysfunction,
hypoperfusion, or hypotension
sepsis-induced hypotension despite adequate fluid resuscitation
along with the presence of perfusion abnormalities causing organ
dysfunction that may include lactic acidosis, oliguria, or an acute
alteration in mental status
7. Concerns with the previous sepsis definition…
The Problem with SIRS
Inflammation and related pathways take center stage
Adapted from: Bone RC et al. Chest. 1992;101:1644-55.
Opal SM et al. Crit Care Med. 2000;28:S81-2.
9. SEPSIS -3
life-threatening
organ dysfunction caused
by
dysregulated host response
to infection
Sepsis
Severe sepsis
Septic
shock
Suspected or
documented
infection and an
acute increase of
≥2 SOFA points
Subset of sepsis in which
underlying circulatory and
cellular/metabolic
abnormalities are profound
enough to substantially
increase mortality
Despite adequate fluid
resuscitation
vasopressor therapy
needed to elevate MAP
≥65 mmHg and
lactate >2 mmol L−1
10. 1.Altered mental status (GCS
score <15)
2.Systolic blood pressure
<100 mmHg
3.Respiratory rate >22/min
qSOFA
If 2/3 of these 3 criteria are positive, the qSOFA
would be positive!
14. CASE HISTORY
• 64 year old female
• H/O Ca tongue (Operated in 2018), completed
Chemotherapy & Radiotherapy (Last RT 1
month back)
• C/O constipation
• C/O Abdominal distension & pain since
yesterday
• C/O fever, low grade & breahing difficulty and
decreased urine output since today morning
• Presented to Our Hospital ER at 2:15PM
15. Physical Examination - 2:15 PM
• GCS 15/15
• T - 98.6 F
• HR - 100/min
• RR - 22/min
• RR - 90/60 mmhg
• SPO2 - 99% on room Air
• P/A - Soft, Distended, Tenderness - Diffuse
• RS, CVS, CNS - Clinically NAD
20. Surviving Sepsis Campaign : 1 HOUR
BUNDLE (2018)
• Measure lactate level*
• Obtain blood cultures before administering antibiotics.
• Administer broad-spectrum antibiotics.
• Begin rapid administration of 30mL/kg crystalloid for hypotension or lactate level ≥
4 mmol/L.
• Apply vasopressors if hypotensive during or after fluid resuscitation to maintain
MAP ≥ 65 mm Hg.
• * Remeasure lactate if initial lactate is elevated (> 2 mmol/L).
21. Primary Investigations (2-3PM)
• Chest X-Ray - Gas under diaphragm
• PreopMajor, ABG & one set paired aerobic Blood C/S sent
• RBS - 77mg%
• ABG
– pH 7.16
– PO2 113 on room air
– PCO2 13.5
– HCO3 4.7
– Lactate 18
– Na/K/Cl 134/3.8/107
– Hb/HCT 12.8/39.5
22. Antibiotic
Primary Treatment BY 3:30PM
• Inj.CEFOSULBACTAM 3GM IV STAT
• INJ.METRONIDAZOLE 500MG IV STAT
• INJ 25% D/W IV STAT
• INJ NS 1 LITER OVER ONE HOUR
• Foley's Catheterization
Fluid
28. EGDT
Reduced the absolute risk of
in-hospital mortality by 16 %
We recommend the protocolized, quantitative
resuscitation of patients with sepsis- induced
tissue hypoperfusion
During the first 6 hrs , the goals of initial
resuscitation
a) CVP 8–12 mm Hg
b) MAP ≥ 65 mm Hg
c) Urine output ≥ 0.5 ml/kg/hr
d) Superior vena cava oxygenation saturation
(Scvo2) or mixed venous oxygen saturation
(SvO2) 70% or 65%, respectively
29. EGDT DRAWBACKS
An arbitrary CVP as surrogate of fluid status
MAP and urine output as surrogate for
organ perfusion
As marker for O2
utilization
Blood transfusions and ionotropes based on Sc
30. Decision to give fluid should be based on :
• Presence of acute circulatory failure
• Presence of preload responsiveness
• Minimal risk of administering fluid
31. Functional Hemodynamic Monitoring
Assessing preload responsiveness
• Variations in arterial pulse pressure, systolic pressure
• Passive leg raising
• End Expiratory Occlusion Test (EEOT)
• Aortic flow variation (TED)
• Echocardiography – IVC and SVC diameter changes
• Mini Fluid Challenge
• End-tidal carbon dioxide
• Non invasive methods - pulse oximeter pleth signal variability
Assess Fluid Tolerance
• Echocardiography – EF, Diastolic function
• Lung Ultrasound - B-Lines
32.
33. 1 Fluid challenge not required if CVP is high
2 Fluid challenge not done in pulmonary edema
• Hypovolemia due to extravasation into lungs
• If shock, fluid challenge will improve blood pressure
3 No fluid challenge since patient has already received 1
litre of fluid in last 1 hour
4 Must continue fluid challenge since CVP is low
Misconceptions in Fluid Challenge
34.
35. RELATIVE EFFECTS OF COMMON VASOACTIVE
MEDICATIONS ON ADRENERGIC RECEPTORS
AGENT (typical dosages) ß-1 ß-2 α-1
Isoproterenol (2-10 ug/min) +++++ +++++ 0
NE (0.01-3 ug/kg/min) +++ ++ +++++
Epinephrine
(Infusion: 0.01 to 0.10 ug/kg/min)
++++ +++ +++++
Phenylephrine
(Infusion: 0.4 to 9.1 ug/kg/min)
0 0 +++++
Dopamine
(2.0 to 20 ug /kg/min, max 50 ug/kg/min )
++++ ++ +++
Dobutamine
(2.0 to 20 ug /kg/min, max 40 ug/kg/min )
+++++ +++ +
- Overgaard CB. Circulation 2008
36.
37. Antibiotics
• We suggest empiric combination therapy
(using at least two antibiotics of different
antimicrobial classes) aimed at the most
likely bacterial pathogen(s) & having good
concentration at suspected site of
infection for the initial management of
septic shock.
– (Weak recommendation; low quality of
evidence)
38. Antibiotics
• We suggest that combination therapy not be
routinely used for on-going treatment of
most other serious infections, including
bacteremia and sepsis without shock.
– (Weak recommendation; low quality of
evidence).
• We recommend against combination therapy
for the routine treatment of neutropenic
sepsis/bacteremia.
– (Strong recommendation; moderate
quality of evidence).
39. Know your local organisms & sensitivity.
Because that determines your antibiotic.
40. Further Treatment (4-5PM)
• RL 500CC + 500CC BOLUS OVER 1 HOUR
• Inj HYDROCORTISONE 200MG IV STAT
• INJ ASCORBIC ACID 1GM IV STAT
• INJ MEROPENAM 2GM IV STAT
(CEFOSULBACTAM STOPPED)
• NORADRENALINE INFUSION
• CENTRAL & ARTERIAL LINE INSERTION
41. A target of no more than 6 to 12 hours after
diagnosis appears to be sufficient for most
cases
42. FURTHER TREATMENT (6PM)
• After primary resuscitation, patient shifted to
OT by 6:15pm
• Sigmoid diverticular perforation and peritonitis
- Exploratory Laprotomy & Hartman Procedure
done, Pus C/S sent intraop.
• Patient shifted to ICU with Nasotracheal &
Nasogastric tube and drains in situ at 9:00 PM
43.
44. Further course in ICU (POD 0-3)
• PATIENT SEDATED
• HR 100/MIN, BP 100/70 WITH NORAD ( 8MG/50ML)
@ 5ML/HR
• ON CONTROLLED MODE OF VENTILATOR
• 2.5 LITRE I/P & 700ML URINE OUTPUT ON ARRIVAL
• 40-50ML/HR URINE AFTER ICU ADMISSION
• Weaning from ventilator started from POD1,
vasopressors tappered
• Decreased urine output on POD1 – 5% Albumin
100ml given in addition to manitainance IV fluid
45.
46. POD-2 to POD-3
• On T-piece for 24 hours on POD2, passing good
urine, vasopressors tappered and stopped.
• Extubated on POD 3
• Pus C/S - E.Coli - Sensitive to BL-BLI,
Quinolones, Aminoglycosides, Carbapenams,
Tigecycline, Fosfomycin, TMP-SMZ,
Chloramphenicol
• Blood C/S - Negative
47. Antimicrobial Therapy
Antibiotic Stewardship
We recommend that empiric antimicrobial therapy be
narrowed once pathogen identification and sensitivities are
established and/or adequate clinical improvement is noted.
(BPS)
We suggest that an antimicrobial treatment duration of 7-10
days is adequate for most serious infections associated with
sepsis and septic shock.
(Weak recommendation; low quality of evidence)
We recommend daily assessment for de-escalation of
antimicrobial therapy in patients with sepsis and septic
shock.
(BPS)
We recommend that dosing strategies of antimicrobials be
optimized based on accepted pk/pd principles and specific
drug properties in patients with sepsis or septic shock
(BPS)
49. POD4 onwards
• Vital stable
• Mobilized
• Maintainance IV fluid as per electrolyte & daily
intake output.
• Shifted to ward
• Meropenam continued for total 8 days
• Stoma started functioning & orally liquid diet
started from POD4.
• Soft diet started from POD5.
• Patient discharged from ward on POD9.
54. www.survivingsepsis.org
Malbrain, M.L.N.G., Regenmortel, N., Saugel, B. et al. Principles of fluid management and stewardship in
septic shock: it is time to consider the four D’s and the four phases of fluid therapy. Ann. Intensive
Care 8, 66 (2018)
LIFTL : https://lifeinthefastlane.com/
UpToDate : www.uptodate.com